Inivata Ltd United Kingdom

Dr John Beeler
VP Bus Dev 

Intract Pharma United Kingdom

Organisation type
Mr Bill Lindsay
Prof Abdul Basit

Invicro London LLC United Kingdom

Invicro was founded with a mission of improving the role and function of imaging in translational drug discovery and development.  To this effort we offer a suite of services and software with applications ranging from tissue to human, from target identification to Phase IV trials across the entire electromagnetic spectrum of imaging techniques.

Organisation type
Mr George Abe
Dr Jack Hoppin

Jupiter Diagnostics United Kingdom

When our CEO, Chris Ball worked as a doctor, he discovered that an urgent blood test usually meant waiting around for hours to get a result - and this was in a busy hospital. While working at Johnson & Johnson, he saw how rapid blood glucose testing could empower patients and accelerate clinical decision-making.  

However no rapid and accurate blood testing was widely available, so he began to look for technology which could deliver high-quality affordable blood testing anywhere. The result is Jupiter Diagnostics.
Dr Christopher Ball

Mironid United Kingdom

Mironid Limited is an innovative new drug discovery company that develops proprietary drug candidate molecules by modulating the activity of key cell signalling proteins. This allows us to access multiple therapeutic areas for exploitation. Our current drug discovery pipeline is aimed at developing novel treatments for degenerative kidney diseases, chronic inflammatory diseases and cancer.

Dr Neil Wilkie

Nanomerics Ltd United Kingdom

Professor Ijeoma Uchegbu
Chief Scientific Officer 

NIHR Clinical Research Network United Kingdom

Mr Matthew Cooper
Business Development & Marketing Director 

Oppilotech Ltd United Kingdom

We are building the most detailed, dynamic, in-silico model of bacterial cell envelope biogenesis, ever assembled. The model is being utilised as a platform to discover and develop an internal pipeline of new antibacterial drugs.

Dr Ajay Mistry
Dr John George
Dr Cora Griffin

OxStem United Kingdom

OxStem is a drug discovery company, spun-out from the University of Oxford, with the unique vision of developing in-situ cell programming therapies to treat what are typically (but certainly not exclusively) age-related conditions, such as Dementia, Heart Failure, Macular Degeneration (the leading cause of blindness in the developed world), Diabetes and Oncology. 

The idea is straightforward - to use the Stem Cell and Medicinal Chemistry expertise within Chemistry and its associated partners at Oxford to identify new classes of drugs that can re-program or stimulate existing endogenous cells - awakening previously defunct or dormant cellular processes.

Dr Michael Stein
Chairman and CEO 
Dr Carolyn Porter
Chief Business Officer 
Mr Raymond Spencer

Pneumagen Ltd United Kingdom

Start-up Biotech
Mr Douglas Thomson